Investor Presentaiton slide image

Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D iber/mezi Alnuctamab demonstrates deep and durable responses in RRMM Response, % Overall Response Rate: Efficacy supports the optimal Phase 3 dose¹ 100 80 50 60 40 40 20 20 0 ORR = 41%2 14 ■SCR ■CR VGPR ORR = 65% PR 19 38 14 7 7 8 <30-mg target dose 30-mg target dose (n=29) (n=26) Deep and durable responses with clinically important MRD negativity1 Patients who achieved a response (n=29) Safety¹ 86% of responses ongoing and mDOR not reached Grade ≥3 n=73 CRS 0 ICANS 0 SCR CR MRD neg (10-6) MRD neg (10-5) Infections 10% VGPR PR PD Ongoing ▲ Death Hematologic: Neutropenia 42% Anemia 25% • Thrombocytopenia 14% T T T T T T T 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Time (months) Responses deepened over time, with CRS limited to low-grade, short-lived events (median duration 2 days) Ill Bristol Myers Squibb™ 1. Wong SW, et al. EHA 2023 [Poster #P883]. 2. Values do not add to 41% due to rounding. Not for Product Promotional Use 85
View entire presentation